药明康德：美国新兴生物技术国家安全委员会报告牵强附会且毫无根据

Core Viewpoint - WuXi AppTec has responded to recent allegations made by the U.S. National Emerging Biotechnology Security Council, asserting that the company has never unauthorizedly transferred U.S. clients' data or intellectual property to third parties [1] Group 1: Company Response - The company’s Vice Chairman and Global Chief Investment Officer, Hu Zhengguo, emphasized the baseless nature of the claims made in the 215-page report by the U.S. council [1] - WuXi AppTec has communicated with relevant U.S. government agencies to clarify the facts surrounding these allegations [1] Group 2: Industry Context - The U.S. National Emerging Biotechnology Security Council's report claims that WuXi AppTec is "deeply embedded in the U.S. biopharmaceutical supply chain" [1]